CHINA MEDICAL SYSTEMS Aktie

 

SHENZHEN, CHINA, March 21, 2025 (GLOBE NEWSWIRE) -- On March 17, China Medical System Holdings Limited (“CMS” or the “Company”) released its 2024 annual results. The Company recorded a turnover of RMB7,469 million, representing a year-on-year decrease of 6.8%; in the case that all medicines were directly sold by the Company, the turnover would be RMB8,622 million, representing a year-on-year decrease of 9.0%. Profit for the year was RMB1,613 million, and normalized profit for the year that excluding the provisions of impairment losses on related assets was RMB 1,714 million. The results announcement shows that in 2024, the performance decline of the Company was mainly influenced by the implementation of the National Volume Based Procurement (the “National VBP”), resulting in a year-on-year turnover (in the case that all medicines were directly sold by the Company) decrease of 28.8% to RMB2,691 million for three original drugs that were not selected....

SHENZHEN, CHINA, Feb. 14, 2025 (GLOBE NEWSWIRE) --  In February 11th 2025, with a Corporate Sustainability Assessment (CSA) score of 61, surpassing 93% of global peers, China Medical System Holdings Limited (“CMS” or the “Group”) has been included in the S&P Global Sustainability Yearbook 2025 (the “Yearbook 2025”). This marks the Group's first inclusion in the global edition of S&P Global Sustainability Yearbook (the “Yearbook”), following the S&P Global Sustainability Yearbook (China Edition) inclusion for consecutive two years....

SHENZHEN, CHINA, Jan. 24, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 24 January 2025, the Group through subsidiaries of the Company entered into a Collaboration Agreement with Hunan Mabgeek Biotechnology Co., Ltd. (“Mabgeek Biotechnology”) and its subsidiary for Class 1 innovative drug anti-IL-4Rα humanized monoclonal antibody injection MG-K10 (“MG-K10” or the “Product”). The Group has obtained the co-development right as specifically agreed upon in the Agreement and exclusive commercialization right to the Product in Mainland China, Hong Kong Special Administrative Region, Macao Special Administrative Region, Taiwan Region and Singapore (the “Territory”); Mabgeek Biotechnology will support the commercialization activities and is responsible for the sale and supply of the Product. The collaboration term is perpetual....

SHENZHEN, CHINA, Jan. 08, 2025 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 8 January 2025, the Group through a wholly-owned subsidiary of the Company entered into a License, Collaboration and Distribution Agreement  (the “Agreement”)  with Alpha Cognition Inc. (“Alpha”) of the improved new drug ZUNVEYL（benzgalantamine delayed-release tablets）(“ZUNVEY” or  the “Product”)  for the treatment of mild-to-moderate dementia of the Alzheimer's type. The Group is entitled to an exclusive right to develop, register, manufacture, import, export and commercialize the Product in Asia (excluding Japan), Australia and New Zealand (the “Territory”), Alpha reserves the right to manufacture and supply in the Territory. The term of cooperation commences on the effective date of the Agreement and extends for twenty years, which may be automatically renewed every five ye...

SHENZHEN, CHINA, Dec. 08, 2024 (GLOBE NEWSWIRE) -- On 6 December, China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that the first prescriptions for the innovative drug Lumeblue® (Methylthioninium Chloride Enteric-coated Sustained-release Tablets) (the “Product”) have been issued in China, which marks that the first oral methylthioninium chloride enteric-coated sustained-release tablets in China has officially entered clinical application. The Product is indicated for enhancing visualization of colorectal lesions in adult patients undergoing screening or surveillance colonoscopies....

SHENZHEN, CHINA, Dec. 02, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 2 December 2024, the Group through a wholly-owned subsidiary of the Company entered into an Exclusive Commercialization Agreement (the “Agreement”) with Atom Therapeutics Co., Ltd (hereinafter referred to as “Atom Therapeutics”, formerly named as “Jiangsu Atom Bioscience and Pharmaceutical Co., Ltd.”) of class 1 innovative drug ABP-671 for the treatment of gout and hyperuricemia (the “Product”). In accordance with the Agreement, the Group is entitled to an exclusive commercialization right of the Product in Mainland China, Hong Kong Special Administrative Region and Macao Special Administrative Region. The term of cooperation commences on the effective date of the Agreement and extends for ten years from the date the Product is first approved for market launch in Mainland China (the "Autho...

SHENZHEN, CHINA, Oct. 18, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Group” or “CMS”) is pleased to announce that on 18 October, the first batch of prescriptions of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) for qualified vitiligo patients were issued in the Greater Bay Area, at Zhongshan Chen Xinghai Hospital of Integrated Traditional Chinese and Western Medicine, Foshan Fosun Chancheng Hospital, and Dongguan Songshan Lake Tungwah Hospital. The Product's new drug application (NDA) was approved by the Pharmaceutical Administration Bureau (ISAF) of Macau on 11 April 2024, and subsequently the Product was approved by the Guangdong Provincial Medical Products Administration on August 19 through the "Hong Kong and Macau Medicine and Equipment Connect" policy, which officially introduced ruxolitinib cream for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age, providing a novel t...

SHENZHEN, CHINA, Sept. 24, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on September 24, 2024, the New Drug Application (NDA) for vitiligo indication of ruxolitinib phosphate cream (the “ruxolitinib cream” or the “Product”) has been accepted by the National Medical Products Administration of China (NMPA). This is another substantial milestone for ruxolitinib cream in China, following the approval for Urgent Clinical Import by Hainan Medical Products Administration and approval for marketing in Macau for vitiligo, and it is also a key step in benefiting over ten million of patients with vitiligo in China....

Das Instrument 2M7C KYG211081248 CHINA M.SYS.H.CONS.DL-005 EQUITY wird cum Dividende/Zinsen gehandelt am 28.08.2024 und ex Dividende/Zinsen am 29.08.2024 The instrument 2M7C KYG211081248 CHINA M.SYS.H.CONS.DL-005 EQUITY has its pre-dividend/interest day on 28.08.2024 and its ex-dividend/interest day on 29.08.2024...

CMS enters the "New Product Era" driven by exclusive and innovative products, with exclusive and innovative drugs revenue accounts for over 56%. CMS enters the "New Product Era" driven by exclusive and innovative products, with exclusive and innovative drugs revenue accounts for over 56%....

SHENZHEN, CHINA, Aug. 05, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 30 July 2024, the New Drug Application (NDA) for an additional indication of Methotrexate Injection (the “Product”) has been approved by the National Medical Products Administration of China (NMPA). The Product is a small-volume methotrexate injection with various strengths for the treatment of active rheumatoid arthritis (RA) in adult patients. The Group was granted a certificate of drug registration on 5 August 2024....

SHENZHEN, CHINA, July 16, 2024 (GLOBE NEWSWIRE) --  In July 2024, China Medical System Holdings Limited (“CMS” or the “Group”) has once again been recognized for its outstanding performance and continuous progress in sustainable development. CMS was reincluded in the 2024 Sustainability Yearbook (China Edition) issued by S&P Global, a global-leading corporate sustainability assessment institution, and maintained its "AA" rating in the updated MSCI (Morgan Stanley Capital International) ESG Rating Report....

SHENZHEN, CHINA, June 25, 2024 (GLOBE NEWSWIRE) -- On June 25, China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) announced the completion of dosing for the first subject in the phase III bridging trial of ruxolitinib cream (the “Product”) in atopic dermatitis (“AD”) in China. This is another substantial clinical development milestone for ruxolitinib cream in China, following the approval for Urgent Clinical Import by Hainan Medical Products Administration and approval for marketing in Macau for vitiligo....

SHENZHEN, CHINA, June 18, 2024 (GLOBE NEWSWIRE) -- China Medical System Holdings Limited (the “Company”, together with its subsidiaries, the “Group” or “CMS”) is pleased to announce that on 11 June 2024, the New Drug Application (NDA) of the Group's innovative drug methylthioninium chloride enteric-coated sustained-release tablets (Lumeblue®) (the “Product”) has been approved by the National Medical Products Administration of China (NMPA). The drug registration certificate was obtained on 18 June 2024. The Product is indicated to enhancing visualisation of colorectal lesions in adult patients undergoing screening or surveillance colonoscopy, and it is the first oral methylthioninium chloride enteric-coated sustained-release tablets in China. The Group will synergize with existing gastroenterology products and resources to advance the commercialization and academic promotion related works of the Product in an orderly manner, aiming to achieve nationwide large-scale clinical application...